abstract |
FIELD: biotechnology. n SUBSTANCE: present invention relates to biotechnology, namely to production of versions of albumin with changed half-life period in plasma in comparison with initial albumin, and can be used in medicine. Version of albumin is obtained, containing one or more substitutes relative to SEQ ID NO: 2, selected from following: 1) E492A, C, D, F, G, H, I, K, L, M, N, Q, R; 2) K500I, R; 3) N503H; 4) E505Q; 5) H510D; 6) D550E, H, I, M, N, R, S, W; 7) K573A, C, D, F, G, H, I, L, M, N, P, R, S, V, W, Y; 8) K574D, F, G, H, I, L, M, P, R, S, T, V, W, Y; 9) A578F; 10) S579C; 11) Q580I, K, M, R, V; or 12) G584D. n EFFECT: invention enables to obtain version of albumin or its fragment, capable to bind with FcRn, or chimeric polypeptide, including said version of albumin or its fragment, with longer half-life period in plasma or increased binding affinity with FcRn in comparison with initial albumin, its fragment or chimeric polypeptide. n 10 cl, 32 dwg, 22 tbl, 22 ex |